Stock Details
ALC is Alcon Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 75.12$. Average daily volumn in 3 months 906.94k. Market cap 36.81B

Stock symbol : ALC. Exchange : NYSE. Currency : USD
Lastest price : 75.11$. Total volume : 665.29k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Alcon Inc. (ALC)
Last Price

Previous Close73.62
Day Range74.34-75.43
Bid75.02 x 1.4k
Ask77.01 x 900
Average Volume906.94k
Market Cap36.81B
52 Week Range63.92-88.78
Trailing P/E80.76
Foward P/E31.17
Dividend (Yield %)0.28%
Ex-Dividend Date2022-05-03

Financial Details

According to Alcon Inc.'s financial reports the company's revenue in 2021 were 8.29B an increase( +33.33%) over the years 2020 revenue that were of 6.83B. In 2021 the company's total earnings were 376M while total earnings in 2020 were -531M(-170.81%).

Loading ...


Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion ... vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Market Cap:
Total Assets:
Total Cash:

News about "Alcon Inc."


Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio

Source from : YAHOO!Finance - 5 days ago

Expands ophthalmic eye drop portfolio leveraging market access expertise and newly created US ophthalmic eye drop sales force. EYSUVIS complements Systane Preservative-Free by exp ...See details»

Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals

Source from : Nasdaq - 5 days ago

Alcon Inc. ALC recently inked a deal to acquire EYSUVIS (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals, Inc. The acquisition adds to Alconโ€™s Systane family ...See details»


The week in bankruptcies: Alcon Contractors and Beacon Cookie Cafe

Source from : The Business Journals - 2 days ago

This week in San Antonio business bankruptcies include Alcon Contractors LLC and Beacon Cookie Cafe Inc.. For the year, San Antonio has recorded 18 business bankruptcy filings.See details»


Alcon Prices EUR 500.0 Million Senior Notes Offering

Source from : YAHOO!Finance - 4 days ago

(SIX/NYSE: ALC), today announced that it has commenced and priced a public offering of EUR 500 million aggregate principal amount of its 2.375% senior notes due 2028 (the "Notes"). The Notes will be ...See details»

Alcon To Acquire EYSUVIS, INVELTYS From Kala Pharma

Source from : Nasdaq - 5 days ago

Alcon (ALC) said it agreed to acquire EYSUVIS (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals Inc. EYSUVIS was approved by the U.S. Food & Drug ...See details»


Alcon to Acquire Eysuvis Drops for Dry Eye Treatment

Source from : INVISIONMAG - 4 days ago

Alcon has signed an agreement to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals Inc. The acquisition of the eye drops (0.25% loteprednol etabonate suspension) โ€œwill complement ...See details»

Alcon Inc. (ALC) CEO David Endicott on Q1 2022 Results - Earnings Call Transcript

Source from : Seeking Alpha - 17 days ago

Greetings and welcome to the Alcon First Quarter 2022 Earnings Conference. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.See details»

Alcon Announces Results of 2022 Annual General Meeting

Source from : Morningstar%2c Inc. - 1 month ago

Bono as newly-elected member of the Board Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed ...See details»


Alcon Celebrates 75 Years of Eye Care Innovation and Access with Brilliant History. Brilliant Future.

Source from : INVISIONMAG - 11 days ago

Brilliant Future. celebration. On May 16, 1947, Alcon Laboratories, Inc. was incorporated and began manufacturing specialty pharmaceutical products in Fort Worth, Texas. Today, Alcon has complementary ...See details»


Kala Announces Entry into Definitive Agreement to Sell EYSUVISยฎ and INVELTYSยฎ to Alcon Inc.

Source from : Yahoo Sport Australia - 5 days ago

Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persistent ...See details»

Corneal Implants Market is reaching US$ 68.4 Mn with CAGR of 13% in 2029|Alcon, Inc., CorneaGen, Aurolab and more

Source from : Medgadget - 22 days ago

The use of corneal implants is gathering momentum around the world, owing to their proven efficacy for the correction of presbyopia by improving near and intermediate vision without any ...See details»

Alcon Inc. Swiss: Alcon Reports First Quarter 2022 Results

Source from : Finanznachrichten - 17 days ago

53 LR Regulaotry News: Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the first quarter ended March 31, 2022. For the first quarter of 2022, worldwide ...See details»

Phacoemulsification Devices Market Share to Grow by USD 559.66 million | 38% of Market Growth to Originate from North America | Technavio

Source from : - 26 days ago

Alcon Inc., Bausch Health Companies Inc., Carl Zeiss AG, Glaukosร‚ Corp., Haag-Streit AG, HOYA Corp., HumanOptics Holding AG, Lenstec Inc., LIGHTMEDร‚ Corp., LUMed ...See details»

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

Source from : Yahoo Sport Australia - 18 days ago

Alcon Inc. ALC is expected to report first-quarter 2022 results on May 10, following market close. In the last-reported quarter, the companyโ€™s earnings per share (EPS) of 56 cents beat the Zacks ...See details»